Nektar TherapeuticsNKTRNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank36
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-222.64%
↓ 12% vs avg
Percentile
P36
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-198.83%
Historical baseline
PeriodValueYoY Change
TTM-222.64%-152.8%
2024-88.08%+67.3%
2023-269.75%+23.3%
2022-351.82%+22.4%
2021-453.18%-75.7%
2020-257.87%+22.8%
2019-333.89%-642.6%
201861.53%+545.3%
2017-13.82%+76.5%
2016-58.79%-